Poly-ICLC is under clinical development by Oncovir and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition success rate ...
Plixorafenib is under clinical development by Fore Biotherapeutics and currently in Phase II for Anaplastic Oligoastrocytoma. According to GlobalData, Phase II drugs for Anaplastic Oligoastrocytoma ...
Representative tissue blocks were immunostained with specific antibodies against IDH1-R132H (dilution 1:200, product no. DIA-H09; Dianova, Hamburg, Germany), P53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback